Immunohistochemical Expression of Vascular Endothelial Growth Factor and Its Correlation with Tumor Grade in Breast Ductal Carcinoma
Breast cancer is the most common cause of cancer-related death in female, after lung cancer. Angiogenesis is essential for tumor growth and metastasis; therefore, antiangiogenesis strategies for treatment of cancer are currently an issue of interest. The role of vascular endothelial growth factor that assumed to be most potent angiogenesis factor is ambiguous in breast cancer. This study described the correlation between vascular endothelial growth factor expression and tumor grade, to define the breast cancer patients who responder to anti-vascular endothelial growth factor therapy. In this research, 200 cases of histological proved invasive ductal breast carcinomas analyzed for vascular endothelial growth factor expression by immunohistochemical staining via cross-sectional descriptive study. Vascular endothelial growth factor expressed in 72.54% of the breast cancers. The VEGF was more detectable in grade I (78.5%) than grade II (77.4%) and grade III (56.2%). There is a significant correlation between tumor grade and VEGF expression (P<0.05). According to this study, VEGF often expressed in invasive ductal breast carcinomas and inversely correlated with tumor grade. Anti-vascular endothelial growth factor postulated more convenience for tumor progression suppression in low grade tumor than high grade tumor.
Lester SC. The breast. In: Kumar V, Abbas AK, Fausto N, Aster JC, editors. Robbins and Cotran Pathologic Basis of Disease, 8th Edition. Philadelphia: Elsevier Saunders; 2010. p. 1066-94.
Adams J, Carder PJ, Downey S, Forbes MA, MacLennan K, Allgar V, Kaufman S, Hallam S, Bicknell R, Walker JJ,Cairnduff F, Selby PJ, Perren TJ, Lansdown M, Banks RE. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF Res 2000;60(11):2898-905.
Rykala J, Przybylowska K, Majsterek I, Pasz-Walczak G, Sygut A, Dziki A, Kruk-Jeromin J. Angiogenesis markers quantification in breast cancer and their correlation with clinicopathological prognostic variables. Pathol Oncol Res 2011;17(4):809-17.
Wu S, Wu X, Zhu W, Cai WJ, Schaper J, Schaper W. Immunohistochemical study of the growth factors, aFGF, bFGF, PDGF-AB, VEGF-A and its receptor (Flk-1) during arteriogenesis. Mol Cell Biochem 2010;343(1-2):223-9.
Wilgus TA, Matthies AM, Radek KA, Dovi JV, Burns AL, Shankar R, DiPietro LA. Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. Am J Pathol 2005;167(5):1257-66.
Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, CareyLA, Subramanian S, West R, Ikpatt F, Olopade OI, van de Rijn M, Perou CM. A compact VEGF signature associatedwith distant metastases and poor outcomes. BMC Med 2009;7:9.
Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer byimmunohistochemical analysis. Mod Pathol 1998;11(2): 155-68.
Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Res 2007;9(6):216.
Zhang XH, Huang DP, Guo GL, Chen GR, Zhang HX, Wan L, Chen SY. Coexpression of VEGF-C and COX-2and its association with lymphangiogenesis in human breast cancer. BMC Cancer 2008;8:4.
Wülfing P, Kersting C, Tio J, Fischer RJ, Wülfing C,Poremba C, Diallo R, Böcker W, Kiesel L. Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clin Cancer Res 2004;10(7):2393-400.
Zhu L, Loo WT, Louis WC. PTEN and VEGF: possiblepredictors for sentinel lymph node micro-metastasis in breast cancer. Biomed Pharmacother 2007;61(9):558-61.
Hoar FJ, Chaudhri S, Wadley MS, Stonelake PS. Coexpression of vascular endothelial growth factor C(VEGF-C) and c-erbB2 in human breast carcinoma. Eur JCancer 2003;39(12):1698-703.
Nakamura Y, Yasuoka H, Tsujimoto M, Yang Q, Tsukiyama A, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I, Kakudo K. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod Pathol 2003;16(4):309-14.
Li YS, Kaneko M, Amatya VJ, Takeshima Y, Arihiro K, Inai K. Expression of vascular endothelial growth factor-C and its receptor in invasive micropapillary carcinoma ofthe breast. Pathol Int 2006;56(5):256-61.
Guo XJ, Chen L, Lang RG, Fan Y, Fu L. Relationship between lymph node metastasis and pathologic features of invasive micropapillary carcinoma of breast. Zhonghua Bing Li Xue Za Zhi 2006;35(1):8-12.
Guo X, Chen L, Lang R, Fan Y, Zhang X, Fu L. Invasivemicropapillary carcinoma of the breast: association of pathologic features with lymph node metastasis. Am JClin Pathol 2006;126(5):740-6.
Al-Dissi AN, Haines DM, Singh B, Kidney BA.Immunohistochemical expression of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 in canine simple mammary gland adenocarcinomas. Can Vet J 2010;51(10):1109-14.
Longatto Filho A, Martins A, Costa SM, Schmitt FC. VEGFR-3 expression in breast cancer tissue is not restricted to lymphatic vessels. Pathol Res Pract 2005;201(2):93-9.
Kamath A, Helie M, Bifulco CB, Li WW, Concato J, Jain D. Lack of immunohistochemical detection of VEGF in prostate carcinoma. Appl Immunohistochem Mol Morphol 2009;17(3):227-32.
Bellamy WT, Richter L, Sirjani D, Roxas C, Glinsmann-Gibson B, Frutiger Y, Grogan TM, List AF. Vascularendothelial cell growth factor is an autocrine promoter ofabnormal localized immature myeloid precursors andleukemia progenitor formation in myelodysplastic syndromes. Blood 2001;97(5):1427-34.
Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004;3(5):391-400.
Jain RK, Duda DG, Clark JW, Loeffler JS. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006;3(1):24-40.
Burstein HJ, Chen YH, Parker LM, Savoie J, Younger J, Kuter I, Ryan PD, Garber JE, Chen H, Campos SM, Shulman LN, Harris LN, Gelman R, Winer EP. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res 2008;14(23):7871-7.
Mohammadi M, Day PJ. The influence of immunosuppressive drugs on vascular endothelial growthfactor production in relation to VEGF -1154 g and -2578 C genotypes. Iran J Immunol 2010;7(4):217-25.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.